AR
Arcturus Therapeutics Holdings Inc.
ARCT · NASDAQ
$14.74 -4.35% (-$0.67)
1M +96.01%
Market Cap $419.0M
P/E Ratio -
Div. Yield -
ROE 46.54%
Piotroski F-Score Weak
1/9Valuation
39 /100
Fair P/B 2.44x
P/S 17.60x
P/FFO N/A
Growth
0 /100
Declining Book val. growth 7.49%
Rev. growth 31.13%
FCF growth N/A
Profitability
20 /100
Weak Net margin 391.90%
Op. margin 433.36%
FCF margin 306.91%
Quality
1 /100
Poor ROE 46.54%
ROA 41.58%
Asset turnover 0.11x
Debt
100 /100
Low Current ratio 5.88x
Debt/Equity 0.13x
Net debt/EBITDA N/A
Stability
18 /100
Unstable Rev. volatility 20.19%
EPS volatility 220.78%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ARCT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Joseph E. Payne
Employees
109
Headquarters
San Diego
Upcoming events
09 NOV
Earnings
Upcoming earnings report